Lexicon Pharmaceuticals I... (LXRX)
Lexicon Pharmaceuticals Statistics
Share Statistics
Lexicon Pharmaceuticals has 361.49M shares outstanding. The number of shares has increased by 46.81% in one year.
| Shares Outstanding | 361.49M |
| Shares Change (YoY) | 46.81% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 79.84% |
| Shares Floating | 179.87M |
| Failed to Deliver (FTD) Shares | 8.61K |
| FTD / Avg. Volume | 0.17% |
Short Selling Information
The latest short interest is 39.1M, so 10.82% of the outstanding shares have been sold short.
| Short Interest | 39.1M |
| Short % of Shares Out | 10.82% |
| Short % of Float | 23.18% |
| Short Ratio (days to cover) | 7.4 |
Valuation Ratios
The PE ratio is -1.91 and the forward PE ratio is -1.86. Lexicon Pharmaceuticals 's PEG ratio is -0.07.
| PE Ratio | -1.91 |
| Forward PE | -1.86 |
| PS Ratio | 281 |
| Forward PS | 1.4 |
| PB Ratio | 3.63 |
| P/FCF Ratio | -2.08 |
| PEG Ratio | -0.07 |
Enterprise Valuation
Lexicon Pharmaceuticals Inc. has an Enterprise Value (EV) of 421.93M.
| EV / Earnings | -2.38 |
| EV / Sales | 350.44 |
| EV / EBITDA | -2.58 |
| EV / EBIT | -2.46 |
| EV / FCF | -2.6 |
Financial Position
The company has a current ratio of 5.6, with a Debt / Equity ratio of 1.14.
| Current Ratio | 5.6 |
| Quick Ratio | 5.58 |
| Debt / Equity | 1.14 |
| Total Debt / Capitalization | 53.25 |
| Cash Flow / Debt | -1.53 |
| Interest Coverage | -13.11 |
Financial Efficiency
Return on equity (ROE) is -1.9% and return on capital (ROIC) is -86.23%.
| Return on Equity (ROE) | -1.9% |
| Return on Assets (ROA) | -0.77% |
| Return on Capital (ROIC) | -86.23% |
| Revenue Per Employee | 4.22K |
| Profits Per Employee | -621.47K |
| Employee Count | 285 |
| Asset Turnover | 0.01 |
| Inventory Turnover | 0.22 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -69.2% in the last 52 weeks. The beta is 1.05, so Lexicon Pharmaceuticals 's price volatility has been higher than the market average.
| Beta | 1.05 |
| 52-Week Price Change | -69.2% |
| 50-Day Moving Average | 0.78 |
| 200-Day Moving Average | 1.44 |
| Relative Strength Index (RSI) | 45.04 |
| Average Volume (20 Days) | 4.96M |
Income Statement
In the last 12 months, Lexicon Pharmaceuticals had revenue of 1.2M and earned -177.12M in profits. Earnings per share was -0.8.
| Revenue | 1.2M |
| Gross Profit | 1.12M |
| Operating Income | -171.75M |
| Net Income | -177.12M |
| EBITDA | -163.46M |
| EBIT | -171.75M |
| Earnings Per Share (EPS) | -0.8 |
Balance Sheet
The company has 22.46M in cash and 106.06M in debt, giving a net cash position of -83.6M.
| Cash & Cash Equivalents | 22.46M |
| Total Debt | 106.06M |
| Net Cash | -83.6M |
| Retained Earnings | -1.77B |
| Total Assets | 321.12M |
| Working Capital | 232.56M |
Cash Flow
In the last 12 months, operating cash flow was -161.9M and capital expenditures -470K, giving a free cash flow of -162.37M.
| Operating Cash Flow | -161.9M |
| Capital Expenditures | -470K |
| Free Cash Flow | -162.37M |
| FCF Per Share | -0.73 |
Margins
Gross margin is 92.94%, with operating and profit margins of -14.26K% and -14.71K%.
| Gross Margin | 92.94% |
| Operating Margin | -14.26K% |
| Pretax Margin | -14.71K% |
| Profit Margin | -14.71K% |
| EBITDA Margin | -13.58K% |
| EBIT Margin | -14.26K% |
| FCF Margin | -13.49K% |
Dividends & Yields
LXRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -109.59% |
| FCF Yield | -61.42% |
Analyst Forecast
The average price target for LXRX is $4, which is 447.9% higher than the current price. The consensus rating is "Buy".
| Price Target | $4 |
| Price Target Difference | 447.9% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
Stock Splits
The last stock split was on May 21, 2015. It was a backward split with a ratio of 1:7.
| Last Split Date | May 21, 2015 |
| Split Type | backward |
| Split Ratio | 1:7 |
Scores
| Altman Z-Score | -8.48 |
| Piotroski F-Score | 4 |